CYTK Share Price Performance
US$66.05
15.42 (30.46%)
15.8% undervalued intrinsic discount
US$78.44
Fair Value
Price US$66.05
AnalystConsensusTarget US$78.44
AnalystLowTarget US$41.00
AnalystHighTarget US$112.91
Fair ValueUS$78.44
Share Pricen/a
Cytokinetics, Incorporated Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 17 Fair Values set on narratives written by author
CYTK Community Narratives
AN
Fair Value US$78.44 15.8% undervalued intrinsic discount
CYTK: Strong Cardiology Data Will Drive Momentum Ahead Of December 2025 FDA Decision
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value US$41 61.1% overvalued intrinsic discount
Regulatory Delays Will Curb Uptake But Will Allow Cautious Progress
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$112.91 41.5% undervalued intrinsic discount
Aging Global Population Will Boost HCM Therapy Uptake
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
CYTK: Strong Cardiology Data Will Drive Momentum Ahead Of December 2025 FDA Decision
Key Takeaways Successful late-stage clinical trials, commercial readiness, and diversification in products position the company for strong growth and reduced dependence on a single therapy. Strategic capital management and global partnerships support expansion, mitigate risks, and enable significant investment in commercialization and ongoing innovation.Read more
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
US$78.44
15.8% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
106.51% p.a.
Profit Margin
16.98%
Future PE
99.45x
Price in 2028
US$96.37
Regulatory Delays Will Curb Uptake But Will Allow Cautious Progress
Key Takeaways Dependence on successful late-stage drug development faces headwinds from payer resistance, pricing pressures, and complex reimbursement landscapes across regions. High R&D spending, lack of marketed products, and ongoing need for capital raise risk continued operating losses and dilution for shareholders.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$41
61.1% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue
48.27% p.a.
Profit Margin
13.95%
Future PE
159.51x
Price in 2028
US$49.75
Aging Global Population Will Boost HCM Therapy Uptake
Key Takeaways Positive clinical data and strong commercialization capabilities could enable rapid market expansion and category leadership in difficult-to-treat heart conditions. Growing unmet demand, robust late-stage pipeline, and industry M&A interest make the company well-positioned for strategic partnerships or acquisition.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$112.91
41.5% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue
119.48% p.a.
Profit Margin
13.95%
Future PE
135.42x
Price in 2028
US$137.01
Trending Discussion
Recently Updated Narratives
AN
CYTK: Momentum Will Build Ahead Of Anticipated FDA Decision Next Year
Fair Value: US$78.44 15.8% undervalued intrinsic discount
9 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Regulatory Delays Will Curb Uptake But Will Allow Cautious Progress
Fair Value: US$41 61.1% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Global Population Will Boost HCM Therapy Uptake
Fair Value: US$112.91 41.5% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Cytokinetics, Incorporated Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -6.15
- -364.69%
- -862.21%
- -233.9%
About CYTK
- Founded
- 1997
- Employees
- 498
- CEO
- WebsiteView website
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
